Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CET
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
01:08p Germany denies devising Greek rescue plan without IMF
01:08p TETRALOGIC PHARMACEUTICALS : Announces Director Appointment
01:07p BERTELSMANN : Pearson plunges as digital switch forces new profit warning
01:07p EU shouldn't mete out trade punishment over Brexit - Johnson
01:07p MERCK & CO., INC. (NYSE : MRK) And Palantir Technologies Inc Agree On Cancer Data Analysis Pact
01:07p BURBERRY : Makes Turnaround Progress As Third-Quarter Sales Rise
01:07p ENERGYSOLUTIONS : Maura Healey wants DPU to pull plug on Eversource rate hike plan
01:07p MOODY : will pay Mass. $12M over securities rating practices
01:07p MITEK : Mobile Verify™ Used by Financial Services Companies Globally to Mitigate Risk and Achieve Compliance
01:07p PRIME MINISTER OFFICE OF INDIA : Cabinet approves Trade Agreement negotiations with Peru
Latest news
Advertisement
Hot News 
-29.46%PEARSON : Warns of Lower Profit, Dividends on Weak U.S. Trading
1.64%BRITISH AMERICAN TOBACCO : Deal Creates Tobacco Giant -- WSJ
4.59%European shares retreat as Pearson plummets
2.88%J D WETHERSPOON : JD Wetherspoon sees higher costs, lower sales
-2.24%EXPERIAN : 3Q Organic Revenue +4%, Keeps FY17 Targets
Most Read News
07:02a DEUTSCHE BANK : Stocks, dollar steady after Trump-led dip
06:15a GOLDMAN SACHS : Finance industry's "worst case" on Brexit spurs contingency plans
01:16a SAMSUNG ELECTRONICS : chief questioned behind closed doors in arrest warrant hearing
01/17 General Motors says to invest additional $1 billion in U.S.
04:02a BERTELSMANN : Pearson shares plunge after another profit warning
Most recommended articles
01/17DJS&P 500, Nasdaq Futures -- Technical Analysis
07:02a DEUTSCHE BANK : Stocks, dollar steady after Trump-led dip
07:00a CITIGROUP : German e-car supplier Aumann plans stock market listing - sources
06:58aDJAsian Rubber Futures End Mostly Higher
06:56a ALIKO DANGOTE : Dangote, China's Sinotruck set up $100 million truck plant in Nigeria